Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 11,571 | 10,254 | 7,599 | 248,304 | 6,052 |
| Cost of Goods | 3,721 | 3,395 | 2,653 | 111,576 | 2,729 |
| Gross Profit | 7,850 | 6,859 | 4,946 | 136,728 | 3,323 |
| Operating Expenses | 52,904 | 52,740 | 51,034 | 94,702 | 50,908 |
| Operating Income | -44,333 | -45,486 | -45,435 | 42,602 | -46,856 |
| Interest Expense | 2,325 | 2,277 | 2,150 | 17,151 | 2,827 |
| Other Income | 2,141 | 2,901 | 187 | 173,542 | 2,084 |
| Pre-tax Income | -44,517 | -44,862 | -47,398 | 198,993 | -47,599 |
| Net Income Continuous | -44,517 | -44,862 | -47,398 | 198,993 | -47,599 |
| Net Income Discontinuous | 8,986 | 342,629 | -9,171 | N/A | 36,848 |
| Net Income | $-35,531 | $297,767 | $-56,569 | $-50,696 | $-10,751 |
| EPS Basic Total Ops | -0.31 | 2.57 | -0.49 | -0.46 | -0.09 |
| EPS Basic Continuous Ops | -0.38 | -0.39 | -0.41 | 1.74 | -0.41 |
| EPS Basic Discontinuous Ops | 0.08 | 2.95 | -0.08 | N/A | 0.32 |
| EPS Diluted Total Ops | -0.31 | 2.57 | -0.49 | -0.46 | -0.09 |
| EPS Diluted Continuous Ops | -0.38 | -0.39 | -0.41 | 1.74 | -0.41 |
| EPS Diluted Discontinuous Ops | 0.08 | 2.95 | -0.08 | N/A | 0.32 |
| EPS Diluted Before Non-Recurring Items | -0.38 | -0.39 | -0.41 | -0.44 | -0.09 |
| EBITDA(a) | $-43,367 | $-44,470 | $-44,389 | $43,635 | $-45,307 |